JXR Reports 7.5% Increase in New Infertility Consultations and 5.2% Rise in Egg Retrieval Cycles for First Four Months

Stock News
05/06

Jinxin Fertility Group (JXR) has announced that through the continuous implementation of operational optimization measures, the group has maintained strong growth momentum. In the four months ended April 30, 2026, the number of new patient visits for infertility reached 16,525, a 7.5% increase compared to the same period in 2025. During the same four-month period, the number of egg retrieval cycles totaled 9,010, representing a 5.2% year-on-year growth. Specifically, the number of new infertility consultations in the Greater Bay Area rose by 17.7% compared to the previous year, while overseas egg retrieval cycles surged by 37.3%. In the Chengdu region, both new infertility consultations and egg retrieval cycles experienced a single-digit decline. Meanwhile, egg retrieval cycles in the Kunming and Wuhan regions increased by 15.5% compared to the same period in 2025, maintaining steady growth.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10